Genenta Science (GNTA) Competitors $3.32 +0.15 (+4.56%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. CRBU, CLLS, SAVA, BDTX, SLS, EPRX, VOR, TARA, GNFT, and MDWDShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Caribou Biosciences (CRBU), Cellectis (CLLS), Cassava Sciences (SAVA), Black Diamond Therapeutics (BDTX), SELLAS Life Sciences Group (SLS), Eupraxia Pharmaceuticals (EPRX), Vor Biopharma (VOR), Protara Therapeutics (TARA), GENFIT (GNFT), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Its Competitors Caribou Biosciences Cellectis Cassava Sciences Black Diamond Therapeutics SELLAS Life Sciences Group Eupraxia Pharmaceuticals Vor Biopharma Protara Therapeutics GENFIT MediWound Caribou Biosciences (NASDAQ:CRBU) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment. Does the media favor CRBU or GNTA? In the previous week, Caribou Biosciences had 2 more articles in the media than Genenta Science. MarketBeat recorded 2 mentions for Caribou Biosciences and 0 mentions for Genenta Science. Caribou Biosciences' average media sentiment score of 1.17 beat Genenta Science's score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Overall Sentiment Caribou Biosciences Positive Genenta Science Neutral Do analysts rate CRBU or GNTA? Caribou Biosciences presently has a consensus target price of $6.67, indicating a potential upside of 129.89%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is CRBU or GNTA more profitable? Genenta Science has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,800.93%. Genenta Science's return on equity of 0.00% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,800.93% -62.35% -49.65% Genenta Science N/A N/A N/A Which has more volatility and risk, CRBU or GNTA? Caribou Biosciences has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Which has better valuation & earnings, CRBU or GNTA? Genenta Science has lower revenue, but higher earnings than Caribou Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.99M27.03-$149.10M-$1.78-1.63Genenta ScienceN/AN/A-$9.64MN/AN/A Do institutionals & insiders believe in CRBU or GNTA? 77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryCaribou Biosciences beats Genenta Science on 8 of the 13 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.67M$3.47B$6.17B$10.68BDividend YieldN/A2.27%5.72%4.83%P/E RatioN/A23.4029.4727.34Price / SalesN/A479.21587.77132.79Price / CashN/A45.2825.8230.35Price / Book4.4910.5212.446.68Net Income-$9.64M-$52.71M$3.32B$276.46M7 Day Performance-4.18%4.72%2.15%0.77%1 Month Performance14.03%15.59%8.41%3.73%1 Year Performance-39.55%13.83%61.67%36.59% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta ScienceN/A$3.33+4.6%N/A-40.5%$63.67MN/A0.007Gap DownCRBUCaribou Biosciences2.5193 of 5 stars$2.44+2.5%$6.67+173.2%+31.5%$227.21M$9.99M-1.37100Positive NewsGap UpCLLSCellectis2.1623 of 5 stars$4.18-5.4%$4.00-4.3%+109.5%$224.56M$49.22M-5.10290Analyst ForecastGap DownSAVACassava Sciences2.6806 of 5 stars$4.43+8.0%$2.00-54.9%-85.2%$214.01MN/A-1.7430BDTXBlack Diamond Therapeutics3.9192 of 5 stars$3.76-1.2%$11.00+192.9%+21.1%$213.81MN/A16.3390News CoverageSLSSELLAS Life Sciences Group1.2943 of 5 stars$2.03+1.5%$7.00+244.8%+69.8%$213.76M$1M-6.3410Gap UpEPRXEupraxia Pharmaceuticals2.5814 of 5 stars$5.94-1.9%$11.00+85.3%+130.3%$213.42MN/A-6.9829Short Interest ↑High Trading VolumeVORVor Biopharma2.8548 of 5 stars$30.77-4.7%$113.83+269.9%N/A$210.77MN/A-0.11140Insider TradeGap UpTARAProtara Therapeutics1.7357 of 5 stars$5.36+0.4%$19.60+265.7%+187.4%$206.79MN/A-3.3130GNFTGENFIT1.9411 of 5 stars$4.10-3.5%$7.00+70.7%-28.6%$205M$76.77M0.00120Positive NewsGap DownMDWDMediWound1.8839 of 5 stars$18.47+1.4%$32.25+74.6%+6.9%$204.83M$20.22M-7.0080 Related Companies and Tools Related Companies Caribou Biosciences Competitors Cellectis Competitors Cassava Sciences Competitors Black Diamond Therapeutics Competitors SELLAS Life Sciences Group Competitors Eupraxia Pharmaceuticals Competitors Vor Biopharma Competitors Protara Therapeutics Competitors GENFIT Competitors MediWound Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
